Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apabetalone - Resverlogix Corporation

Next Previous
Drug Profile

Apabetalone - Resverlogix Corporation

Alternative Names: RVX-000222; RVX-208

Latest Information Update: 02 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Resverlogix Corporation
  • Class Anti-inflammatories; Antidementias; Antihyperlipidaemics; Antihypertensives; Antiretrovirals; Antivirals; Cardiovascular therapies; Ethers; Ketones; Nootropics; Quinazolines; Small molecules; Urologics; Vascular disorder therapies
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Phase III Acute coronary syndromes; Atherosclerosis; Low HDL cholesterol; Vascular dementia
  • Phase II/III COVID 2019 infections; Type 2 diabetes mellitus
  • Phase II Prediabetic state
  • Preclinical Heart failure
  • No development reported Alzheimer's disease; Fabry's disease; HIV infections; Pulmonary arterial hypertension; Renal failure

Most Recent Events

  • 15 Apr 2025 Phase-II/III clinical trials in COVID-2019 infections in Jordan, Saudi Arabia, United Arab Emirates (PO) (NCT06590324)
  • 15 Apr 2025 Phase-II/III clinical trials in Type 2 diabetes mellitus in Jordan, Saudi Arabia, United Arab Emirates (PO) (NCT06590324)
  • 16 Nov 2024 Preclinical trials in Heart failure in Canada (PO), before November 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top